Rezdiffra (Resmetirom) Effect on Free T3

How Resmetirom Works on Thyroid Receptors

Resmetirom was designed to mimic thyroid hormone activity exclusively at the THR-β receptor, which predominates in the liver. By binding THR-β with roughly 28-fold selectivity over THR-α, it stimulates hepatic lipid metabolism, reduces liver fat, and promotes resolution of steatohepatitis without triggering the cardiac, bone, or muscle effects associated with systemic thyroid hormone excess 1.

Why Free T3 Drops

The decline in Free T3 is a pharmacodynamic consequence of selective THR-β activation. When resmetirom binds hepatic THR-β, the hypothalamic-pituitary-thyroid (HPT) axis reads this as increased thyroid hormone signaling in the liver. The hypothalamus and pituitary respond by mildly suppressing thyrotropin-releasing hormone (TRH) and TSH secretion. Less TSH means less stimulation of the thyroid gland, which produces less T4. Since roughly 80% of circulating T3 comes from peripheral conversion of T4 (primarily in the liver and kidneys), the net result is a measurable drop in Free T3 2.

Selectivity Matters

The THR-α receptor drives cardiac chronotropy, bone turnover, and skeletal muscle metabolism. Because resmetirom largely bypasses THR-α, patients do not typically develop tachycardia, osteoporosis, or the hypermetabolic state seen with exogenous T3 supplementation. The Free T3 reduction reflects feedback recalibration, not tissue-level hypothyroidism 1.

What MAESTRO-NASH Found About Free T3

The MAESTRO-NASH trial (N=966) was the key phase 3 study that led to FDA approval. It enrolled adults with biopsy-confirmed MASH and fibrosis stage F1B through F3, randomizing them to resmetirom 80 mg, resmetirom 100 mg, or placebo for 52 weeks 1.

T3 Reductions by Dose

Thyroid function was a prespecified safety endpoint. At week 52, mean Free T3 declined by approximately 15% in the 80 mg group and approximately 22% in the 100 mg group versus minimal change in the placebo arm. The effect was dose-dependent and consistent across subgroups stratified by age, sex, baseline BMI, and fibrosis stage 1.

TSH and Free T4 Changes

TSH showed a small compensatory increase, but mean values remained within the laboratory reference range for most patients. Free T4 declined modestly (roughly 10-15%), consistent with reduced TSH drive being partially offset by the drug's direct hepatic effects. No participants required levothyroxine initiation solely because of resmetirom-induced thyroid changes during the 52-week study period 1.

Time Course

Free T3 reductions appeared as early as week 4 and plateaued by week 12 to 16. This timeline aligns with the drug reaching steady-state plasma concentrations (resmetirom half-life is approximately 50 hours) and the HPT axis reaching a new equilibrium 3.

Clinical Significance of Free T3 Reduction

A 15-25% reduction in Free T3 sounds alarming. It usually is not. Here is how to interpret it in context.

Most Patients Stay Euthyroid

In MAESTRO-NASH, the vast majority of patients maintained Free T3 values above the lower limit of normal. Only a small percentage (reported at <5%) had transient Free T3 values below the reference range, and these values normalized on repeat testing without dose adjustment in most cases 1.

Symptoms to Watch For

Because THR-α is largely spared, the classic hypothyroid symptoms (fatigue, cold intolerance, constipation, weight gain, bradycardia) were not reported at increased frequency in the resmetirom arms compared to placebo. When fatigue did occur, it was mild, transient, and difficult to distinguish from the underlying MASH-related fatigue common in this population 1.

When the Drop May Matter More

Certain populations deserve closer attention. Patients with pre-existing subclinical hypothyroidism (TSH 4.5-10 mIU/L with normal Free T4) could theoretically tip into overt hypothyroidism when resmetirom suppresses residual thyroid function. The same applies to patients who have had partial thyroidectomy, radioactive iodine ablation, or are on a stable but borderline-adequate dose of levothyroxine. MAESTRO-NASH excluded patients with uncontrolled thyroid disease, so real-world data in these subgroups remains limited 4.

Monitoring Recommendations

The FDA prescribing information for Rezdiffra includes thyroid function testing as part of routine monitoring. Based on trial data and expert consensus, a practical monitoring framework looks like this.

Baseline Assessment

Before starting resmetirom, obtain a complete thyroid panel: TSH, Free T4, and Free T3. This establishes individual reference values. Patients with abnormal baseline thyroid function should have their thyroid disease optimized before initiating therapy. The Endocrine Society recommends treating overt hypothyroidism to a TSH target of 0.5-4.5 mIU/L before adding medications known to alter thyroid economy 5.

Early Follow-Up

Repeat thyroid panel at 8-12 weeks. By this point, the HPT axis has reached its new steady state on resmetirom. If Free T3 has dropped but remains within the reference range and the patient is asymptomatic, no intervention is needed. If Free T3 falls below range or TSH rises above 10 mIU/L, consider endocrinology consultation.

Ongoing Monitoring

After the initial check, repeat thyroid function every 6-12 months or sooner if the patient develops symptoms consistent with hypothyroidism. Dose changes (switching from 80 mg to 100 mg or vice versa) should prompt a repeat thyroid panel 8 weeks after the adjustment 6.

What About Patients Already on Levothyroxine?

Patients taking levothyroxine for hypothyroidism may need dose adjustment after starting resmetirom. The drug's suppression of endogenous TSH can alter the feedback dynamics, making it harder to interpret TSH as a sole guide for levothyroxine dosing. In these patients, monitoring both Free T4 and Free T3 (not just TSH) provides a more complete picture 5.

Resmetirom Compared to Exogenous T3 Effects

Understanding how resmetirom differs from simply giving a patient liothyronine (synthetic T3) clarifies why the Free T3 reduction is expected rather than paradoxical.

Opposite Directions on T3

Liothyronine raises Free T3 directly. It floods all tissues (heart, bone, brain, liver) with active thyroid hormone. Resmetirom does the opposite at the systemic level. It tells the liver "you have enough thyroid hormone signaling" without actually increasing circulating T3. The pituitary responds by reducing TSH output, and circulating T3 falls 2.

Hepatic Effect Is Similar

Inside the liver, the functional outcome is comparable. Both liothyronine and resmetirom increase THR-β-mediated gene transcription, promoting fatty acid oxidation, LDL receptor upregulation, and cholesterol catabolism. Resmetirom achieves this without the cardiovascular risks of supraphysiologic T3 exposure. In MAESTRO-NASH, mean LDL cholesterol fell by 13-16% in the resmetirom arms, a direct readout of hepatic THR-β activation 1.

Bone and Heart Safety

A phase 2 bone density substudy found no significant change in lumbar spine or femoral neck bone mineral density over 52 weeks of resmetirom use. Heart rate did not increase. These findings confirm that the THR-α-mediated effects feared with thyroid hormone analogs are absent with resmetirom at approved doses 3.

Drug Interactions That Could Compound Thyroid Effects

Several medications commonly used in the MASH population can independently affect thyroid function or interact with resmetirom pharmacokinetics.

Amiodarone

Amiodarone contains iodine and can cause both hypo- and hyperthyroidism. A patient on amiodarone who starts resmetirom faces additive risk of hypothyroidism from two independent mechanisms. MAESTRO-NASH did not enroll patients on amiodarone, so this combination lacks clinical trial data. Close monitoring (every 4-6 weeks initially) is appropriate 7.

Statins

Resmetirom increases hepatic LDL receptor expression, which may amplify the LDL-lowering effect of statins. While this is generally beneficial, the combination could increase the risk of statin-related adverse events in some patients. In MAESTRO-NASH, concomitant statin use was permitted, and no excess hepatotoxicity or myopathy signal was detected 1.

Bile Acid Sequestrants

Cholestyramine and colesevelam can bind thyroid hormones in the gut, reducing T4 and T3 absorption. For patients already on levothyroxine, adding a bile acid sequestrant while on resmetirom creates a triple hit to thyroid hormone availability. If bile acid sequestrants are necessary, separate dosing by at least 4 hours from both levothyroxine and resmetirom 5.

Post-Marketing Thyroid Safety Data

Resmetirom received accelerated FDA approval in March 2024, so long-term post-marketing data remains early. The ongoing open-label extension of MAESTRO-NASH (tracking patients beyond 52 weeks) and the confirmatory MAESTRO-NAFLD-1 trial will provide additional safety data 6.

What the FDA Label Says

The Rezdiffra prescribing information lists thyroid function test abnormalities as an identified risk. It recommends thyroid testing before and during treatment, without specifying exact intervals, leaving the schedule to clinical judgment. The label does not contraindicate use in patients with pre-existing hypothyroidism, though it advises that thyroid disease should be "adequately treated" before starting therapy 6.

REMS and Monitoring Requirements

Resmetirom does not carry a Risk Evaluation and Mitigation Strategy (REMS) related to thyroid function. The monitoring framework described above represents best-practice guidance drawn from the clinical trial protocols and the prescribing information, not a regulatory mandate.

Practical Takeaway for Patients

If your clinician prescribed Rezdiffra for MASH and your follow-up labs show a lower Free T3 than baseline, that result is expected. It does not mean the drug is harming your thyroid. It means the drug is working in the liver, and your pituitary gland is responding normally to that signal. The question that matters: is your Free T3 still within the reference range, and are you free of hypothyroid symptoms? If both answers are yes, no change in therapy is needed. If Free T3 drops below range or you develop persistent fatigue, weight gain, or cold sensitivity, contact your prescribing physician for repeat labs and possible referral to endocrinology.

Target Free T3 reference range at most laboratories: 2.3-4.2 pg/mL. A drop from 3.8 to 3.0 pg/mL is typical on resmetirom 100 mg and clinically insignificant.